- Home
- HCWB vs EPWK Comparison
HCWB vs EPWK Comparison
Compare HCWB & EPWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCWB
- EPWK
- Stock Information
- Founded
- HCWB 2018
- EPWK 2011
- Country
- HCWB United States
- EPWK China
- Employees
- HCWB N/A
- EPWK N/A
- Industry
- HCWB Biotechnology: Pharmaceutical Preparations
- EPWK
- Sector
- HCWB Health Care
- EPWK
- Exchange
- HCWB Nasdaq
- EPWK Nasdaq
- Market Cap
- HCWB 10.8M
- EPWK 11.0M
- IPO Year
- HCWB 2021
- EPWK 2025
- Fundamental
- Price
- HCWB $4.31
- EPWK $0.48
- Analyst Decision
- HCWB Strong Buy
- EPWK
- Analyst Count
- HCWB 1
- EPWK 0
- Target Price
- HCWB $35.00
- EPWK N/A
- AVG Volume (30 Days)
- HCWB 112.9K
- EPWK 608.3K
- Earning Date
- HCWB 08-13-2025
- EPWK 05-27-2025
- Dividend Yield
- HCWB N/A
- EPWK N/A
- EPS Growth
- HCWB N/A
- EPWK N/A
- EPS
- HCWB N/A
- EPWK N/A
- Revenue
- HCWB $1,445,145.00
- EPWK $20,164,008.00
- Revenue This Year
- HCWB $178.36
- EPWK N/A
- Revenue Next Year
- HCWB N/A
- EPWK N/A
- P/E Ratio
- HCWB N/A
- EPWK N/A
- Revenue Growth
- HCWB N/A
- EPWK 10.25
- 52 Week Low
- HCWB $3.55
- EPWK $0.41
- 52 Week High
- HCWB $100.80
- EPWK $26.00
- Technical
- Relative Strength Index (RSI)
- HCWB 39.51
- EPWK N/A
- Support Level
- HCWB $4.02
- EPWK N/A
- Resistance Level
- HCWB $4.44
- EPWK N/A
- Average True Range (ATR)
- HCWB 0.31
- EPWK 0.00
- MACD
- HCWB 0.06
- EPWK 0.00
- Stochastic Oscillator
- HCWB 11.95
- EPWK 0.00
About HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
About EPWK EPWK Holdings Ltd. Class A Ordinary Shares
EPWK Holdings Ltd create an innovative and efficient crowdsourcing platform to connect businesses with great talents. It operates online marketplace to enable businesses (buyers) and service providers (sellers) to find each other. The platform users consist of buyers who seek talents for their jobs and sellers who offer different talents and skills. The company derives revenue mainly comes from providing various value-added services for users on both supply and demand sides.